Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts - Archive ouverte HAL Access content directly
Journal Articles Biomolecules Year : 2020

Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts

(1) , (1) , (1) , (1) , (1) , (1)
1

Abstract

Parkinson's Disease (PD) is characterized both by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy Bodies. These Lewy Bodies contain the aggregated α-synuclein (α-syn) protein, which has been shown to be able to propagate from cell to cell and throughout different regions in the brain. Due to its central role in the pathology and the lack of a curative treatment for PD, an increasing number of studies have aimed at targeting this protein for therapeutics. Here, we reviewed and discussed the many different approaches that have been studied to inhibit α-syn accumulation via direct and indirect targeting. These analyses have led to the generation of multiple clinical trials that are either completed or currently active. These clinical trials and the current preclinical studies must still face obstacles ahead, but give hope of finding a therapy for PD with time.
Fichier principal
Vignette du fichier
biomolecules-10-00391.pdf (769.07 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-02505663 , version 1 (11-03-2020)

Identifiers

Cite

Margaux Teil, Marie-Laure Arotçarena, Emilie Faggiani, Florent Laferrière, Erwan Bézard, et al.. Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts. Biomolecules, 2020, 10 (3), pp.391. ⟨10.3390/biom10030391⟩. ⟨inserm-02505663⟩

Collections

INSERM CNRS ANR
26 View
100 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More